Elanco Animal Health (ELAN) filed the proposed terms of its IPO this week, planning to raise $1.35 billion at a market cap of $7.7 billion, and begin trading during the week of September 17.
Being spun out of pharmaceutical giant Eli Lilly, Elanco is the #4 global provider of animal health products, behind Zoetis, Boehringer Ingelheim and Merck. Elanco is #1 in medicinal feed additives, #2 in poultry and #3 in cattle. It's getting a lot of attention because #1 player Zoetis, the only major public peer in the $34 billion industry, has consistently beat the market since its 2013 IPO, returning 25% annually.
Fall IPO Preview
Elanco was just one IPO that we highlighted in our Fall 2018 IPO Preview, released earlier this week.
To read the entire article, sign up for a free 7-day trial of IPO Pro, the single, most effective IPO data platform you'll ever need.
Fall IPO Preview
Elanco was just one IPO that we highlighted in our Fall 2018 IPO Preview, released earlier this week.
